Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial-Reference-Cited by-同舟云学术

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Published:2020-08 Issue:8 Volume:21 Page:1099-1109
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Apolo Andrea B,Nadal Rosa,Tomita Yusuke,Davarpanah Nicole N,Cordes Lisa M,Steinberg Seth M,Cao Liang,Parnes Howard L,Costello Rene,Merino Maria J,Folio Les R,Lindenberg Liza,Raffeld Mark,Lin Jeffrey,Lee Min-Jung,Lee Sunmin,Alarcon Sylvia V,Yuno Akira,Dawson Nancy A,Allette Kimaada,Roy Arpita,De Silva Dinuka,Lee Molly M,Sissung Tristan M,Figg William D,Agarwal Piyush K,Wright John J,Ning Yangmin M,Gulley James L,Dahut William L,Bottaro Donald P,Trepel Jane B

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005

2. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986;De Santis;J Clin Oncol,2012

3. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016

4. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial;Sharma;Lancet Oncol,2017

5. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling;Frontiers in Pharmacology;2024-01-10

2. Progress in systemic therapy for advanced-stage urothelial carcinoma;Nature Reviews Clinical Oncology;2023-11-09

3. Current and Emerging Strategies to Treat Urothelial Carcinoma;Cancers;2023-10-08

4. Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy;Journal of Kidney Cancer and VHL;2023-09-26

5. Transarterial Selective Internal Radiation Therapy with Yttrium-90 for Liver Metastatic Urothelial Carcinoma of the Ureter as a Bridging Therapy to Immunotherapy: A Case Report with a 10-Year Follow-Up;Case Reports in Oncology;2023-08-24